DK0980251T3 - Vævsfaktor til påvirkning af blodkardannelse - Google Patents

Vævsfaktor til påvirkning af blodkardannelse

Info

Publication number
DK0980251T3
DK0980251T3 DK98933500T DK98933500T DK0980251T3 DK 0980251 T3 DK0980251 T3 DK 0980251T3 DK 98933500 T DK98933500 T DK 98933500T DK 98933500 T DK98933500 T DK 98933500T DK 0980251 T3 DK0980251 T3 DK 0980251T3
Authority
DK
Denmark
Prior art keywords
tissue factor
blood vessel
vessel formation
influence blood
influence
Prior art date
Application number
DK98933500T
Other languages
Danish (da)
English (en)
Inventor
Peter Nawroth
Katsumi Nakagawa
Youming Zhang
Original Assignee
Merckle Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle Gmbh filed Critical Merckle Gmbh
Application granted granted Critical
Publication of DK0980251T3 publication Critical patent/DK0980251T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Instructional Devices (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK98933500T 1997-05-09 1998-05-08 Vævsfaktor til påvirkning af blodkardannelse DK0980251T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19719652A DE19719652A1 (de) 1997-05-09 1997-05-09 Tissue-Faktor zur Förderung von Wundheilung
DEPCT/DE98/01278 1998-05-07
PCT/DE1998/001306 WO1998051321A1 (de) 1997-05-09 1998-05-08 Tissue-faktor zur beeinflussung von gefässbildung

Publications (1)

Publication Number Publication Date
DK0980251T3 true DK0980251T3 (da) 2002-11-18

Family

ID=7829124

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98933500T DK0980251T3 (da) 1997-05-09 1998-05-08 Vævsfaktor til påvirkning af blodkardannelse

Country Status (16)

Country Link
EP (1) EP0980251B1 (cs)
JP (1) JP2001527555A (cs)
AT (1) ATE222501T1 (cs)
AU (1) AU746782B2 (cs)
CA (1) CA2288117A1 (cs)
CZ (1) CZ293005B6 (cs)
DE (2) DE19719652A1 (cs)
DK (1) DK0980251T3 (cs)
ES (1) ES2184299T3 (cs)
HU (1) HUP0003831A3 (cs)
IS (1) IS5231A (cs)
NO (1) NO995459D0 (cs)
PL (1) PL336662A1 (cs)
PT (1) PT980251E (cs)
SI (1) SI0980251T1 (cs)
WO (1) WO1998051321A1 (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
DE19719652A1 (de) * 1997-05-09 1998-12-03 Merckle Gmbh Tissue-Faktor zur Förderung von Wundheilung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
AU5093593A (en) * 1992-08-28 1994-03-29 Scripps Research Institute, The Inhibition of tumor metastasis via neutralization of tissue factor function
FR2696095B1 (fr) * 1992-09-30 1994-11-25 Inoteb Colle biologique à base de protéines coagulables par la thrombine, enrichie en facteurs plaquettaires, sa préparation et son application.
EP0804562B1 (en) * 1994-07-12 2002-10-09 Human Genome Sciences, Inc. Connective tissue growth factor-2
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
DE19719652A1 (de) * 1997-05-09 1998-12-03 Merckle Gmbh Tissue-Faktor zur Förderung von Wundheilung

Also Published As

Publication number Publication date
NO995459L (no) 1999-11-08
IS5231A (is) 1999-10-26
ES2184299T3 (es) 2003-04-01
WO1998051321A9 (de) 1999-04-01
CZ391299A3 (cs) 2000-04-12
NO995459D0 (no) 1999-11-08
PL336662A1 (en) 2000-07-03
CZ293005B6 (cs) 2004-01-14
EP0980251A1 (de) 2000-02-23
PT980251E (pt) 2003-01-31
AU746782B2 (en) 2002-05-02
HUP0003831A2 (hu) 2001-02-28
EP0980251B1 (de) 2002-08-21
WO1998051321A1 (de) 1998-11-19
HUP0003831A3 (en) 2003-08-28
JP2001527555A (ja) 2001-12-25
AU8331598A (en) 1998-12-08
SI0980251T1 (en) 2003-02-28
DE19719652A1 (de) 1998-12-03
CA2288117A1 (en) 1998-11-19
DE59805246D1 (de) 2002-09-26
ATE222501T1 (de) 2002-09-15

Similar Documents

Publication Publication Date Title
NO944997D0 (no) Trombin-blodfraksjon for anvendelse ved en medisinsk fremgangsmåte
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DE69827192D1 (de) Stent und Stent-Transplantat zur Behandlung von verzweigten Blutgefässen
DK2412368T3 (da) Sammensætning til behandling af ar
DE69725198D1 (de) Künstliches Blutgefäss
DE69022249D1 (de) Knochenwachsapplikator zur Behandlung von Knochengewebe.
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
DK0462426T3 (da) Biokompatible, perforerede membraner og deres anvendelse som kunstig hud
DE50014699D1 (de) Medizinisches Instrument zum Präparieren von Gewebe
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
DK0706348T3 (da) Kirurgisk instrument især til dental kirurgi.
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
DE69617963D1 (de) Behandlung von titandioxidaufachlämmungen mittels scherkräften
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
DK0980251T3 (da) Vævsfaktor til påvirkning af blodkardannelse
WO2002036090A3 (de) Kosmetische pflaster zur hautaufhellung
DE3772051D1 (de) Prothese zur expansion des hautgewebes.
DE3785555D1 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
ATE324905T1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
DE69519219D1 (de) Verwendung von (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamid zur Behandlung von Keratopathie
DE69832075D1 (de) Verwendung von eprosartan zur behandlung von isoliertem systolischem bluthochdrucks
NO984965D0 (no) Komponent B som cicatrisant
DE69819503D1 (de) Verwendung von 7-apha-methyl-17-alpha-ethynyl-estrane derivaten zur behandlung von atherosclerose